SEC Filing Summary: Sonus Pharmaceuticals, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Sonus Pharmaceuticals, Inc. on August 10, 2006. The registrant is a Delaware corporation headquartered in Bothell, Washington. The filing reports a material modification to the rights of security holders effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder rights amendments rather than financial performance.
Material Changes
- Extension of Rights Agreement: The Company executed a Second Amendment to its Amended and Restated Rights Agreement (originally dated July 24, 2002).
- Expiration Date Change: The "Final Expiration Date" of the Rights Agreement was amended from August 23, 2006 to August 23, 2016.
- Term Extension: This amendment extends the term of the Rights Agreement by ten years.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or specific operational risks. The primary contingency noted is the continued existence of the poison pill mechanism (Rights Agreement) for an additional decade, which may impact potential takeover scenarios. The summary description is qualified by reference to Exhibit 3 of Amendment No. 2 to the Company's Form 8-A/A filed on August 14, 2006.
Investor Verification Checklist
- Verify the full text of the Second Amendment to the Amended and Restated Rights Agreement (Exhibit 4.3) to understand specific terms of the extension.
- Review the Form 8-A/A filed on August 14, 2006 for the complete legal description of the rights plan.
- Confirm the impact of the extended rights plan on the company's capital structure and potential acquisition defenses.
- Note the discrepancy in the request metadata (ACHIEVE LIFE SCIENCES) versus the filing content (SONUS PHARMACEUTICALS); this filing pertains to Sonus Pharmaceuticals.